Private Equity

An upcoming Singapore conference reveals how litigation finance is becoming a multi-billion dollar asset class, with Asia as its new, rapidly expanding frontier.

LMC Landscape Partners' latest acquisition of Prestige Landscape Services signals a new era of consolidation in the booming Dallas-Fort Worth market.

Activist investor Corvex Management, citing a 13-year low stock price, demands the Premier Inn owner be sold, escalating a battle over the hotel giant's future.

Wall Financial renews its significant share buyback plan, signaling confidence. But does it mask deeper concerns about debt and a volatile real estate market?

The cell-engineering firm posted a smaller-than-expected loss and announced a share buyback, signaling confidence despite a dip in core Q1 revenue.

Abry Private Debt's latest acquisition with Coller Capital is more than a deal; it's a sign of the explosive growth in the private credit secondaries market.

TSLX prices a $300M bond offering and plans a strategic swap to manage risk, signaling confidence and enhancing its firepower in private credit.

LifeMD posts record subscriber growth in Q1 driven by GLP-1 and women's health, but a planned loss from heavy marketing spend raises key questions.

With backing from Eli Lilly, Cabaletta Bio's $150M financing will accelerate its potentially curative cell therapies for autoimmune diseases.

Bill Ackman's ambitious dual IPO for Pershing Square raised $5 billion but saw shares fall on day one, testing investor faith in his unique structure.

Backed by activist investor Irenic Capital, a new $220M blank-check firm hits Nasdaq, aiming to acquire a target in the aerospace or industrial sectors.

Just seven years after its founding, IEQ Capital sees four founders named to Forbes' elite list. Here's how they built a $42 billion wealth powerhouse.

San Diego's Dunham joins the nation's elite financial firms. Discover the unique 40-year strategy and performance-based fees driving their success.

AI cloud specialist CoreWeave raises another $1 billion in high-yield debt, doubling down on its aggressive expansion to meet insatiable AI demand.

The Dallas-based asset manager taps veteran Rob O’Connor to lead a new platform, capitalizing on surging investor demand for liquidity in private credit.

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

A strategic partnership with 5 Horizons Ventures accelerates Marvel Biosciences' novel drug, MB-204, into human trials for autism, Rett syndrome, and more.

After a period of explosive growth under Owner Resource Group, the tech-forward BPO provider begins a new chapter with Chicago-based private equity firm Frontenac.

A new ultra-low fee for large deals challenges traditional brokers and signals a digital revolution in the multi-billion dollar secondary market.

PMGC Holdings touts major acquisitions and a promising biotech pipeline, but a look at its financials reveals a high-stakes bet on future growth.